Intratumoral Administration of Holmium-166 Acetylacetonate Microspheres: Antitumor Efficacy and Feasibility of Multimodality Imaging in Renal Cancer

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Bult, Wouter ^a,b   Kroeze, Stephanie G C ^a   Elschot, Mattijs ^a   Seevinck, Peter R ^c   Beekman, Freek J ^d,e   de Jong, Hugo W A M ^a   Uges, Donald R A ^b   Kosterink, Jos G W ^b   Luijten, Peter R ^a   Hennink, Wim E ^f   van het Schip, Alfred D ^a   Bosch, J L H Ruud ^a   Nijsen, J Frank W ^a   Jans, Judith J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MILabs   (Netherlands)

^e DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^f UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HOLMIUM 166 ACETYLACETONATE MICROSPHERE; RADIOACTIVE MICROSPHERE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG TISSUE LEVEL; ELECTRON; GAMMA RADIATION; HISTOPATHOLOGY; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR ABLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; FEASIBILITY STUDIES; HOLMIUM; HYDROXYBUTYRATES; KIDNEY NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED BALB C; MICROSPHERES; ORGANOMETALLIC COMPOUNDS; PENTANONES; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TUMOR CELLS, CULTURED;

MUS;

EID: 84872171361     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0052178     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK, (2006) Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst 98: 1331-1334.
3. Kutikov A, Egleston BL, Wong YN, Uzzo RG, (2010) Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J Clin Oncol 28: 311-317.
4. Santos Arrontes D, Fernandez Acenero MJ, Garcia Gonzalez JI, Martin Munoz M, Paniagua Andres P, (2008) Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J Urol 179: 857-861.
5. Lane BR, Abouassaly R, Gao T, Weight CJ, Hernandez AV, et al. (2010) Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116: 3119-3126.
6. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, et al. (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58: 398-406.
7. Heuer R, Gill IS, Guazzoni G, Kirkali Z, Marberger M, et al. (2010) A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 57: 223-232.
8. Muto G, Castelli E, Migliari R, D'Urso L, Coppola P, et al. (2011) Laparoscopic Microwave Ablation and Enucleation of Small Renal Masses: Preliminary Experience. Eur Urol 60: 173-6.
9. Kerkhof EM, Raaymakers BW, van Vulpen M, Zonnenberg BA, Bosch JL, et al. (2011) A new concept for non-invasive renal tumour ablation using real-time MRI-guided radiation therapy. BJU Int 107: 63-68.
10. MacKie S, de Silva S, Aslan P, Ladd L, Houang M, et al. (2011) Super selective radio embolization of the porcine kidney with 90yttrium resin microspheres: a feasibility, safety and dose ranging study. J Urol 185: 285-290.
11. Gao W, Liu L, Liu ZY, Wang Y, Jiang B, et al. (2010) Intratumoral injection of 32P-chromic phosphate in the treatment of implanted pancreatic carcinoma. Cancer Biother Radiopharm 25: 215-224.
12. Coldwell D, Sangro B, Salem R, Wasan H, Kennedy A, (2012) Radioembolization in the Treatment of Unresectable Liver Tumors: Experience Across a Range of Primary Cancers. Am J Clin Oncol 35: 167-77.
13. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, et al. (2009) Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 19: 951-959.
14. Tian JH, Xu BX, Zhang JM, Dong BW, Liang P, et al. (1996) Ultrasound-guided internal radiotherapy using yttrium-90-glass microspheres for liver malignancies. J Nucl Med 37: 958-963.
15. Lin WY, Tsai SC, Hsieh JF, Wang SJ, (2000) Effects of 90Y-microspheres on liver tumors: comparison of intratumoral injection method and intra-arterial injection method. J Nucl Med 41: 1892-1897.
16. Bult W, Seevinck PR, Krijger GC, Visser T, Kroon-Batenburg LM, et al. (2009) Microspheres with ultrahigh holmium content for radioablation of malignancies. Pharm Res 26: 1371-1378.
17. Nijsen JF, Zonnenberg BA, Woittiez JR, Rook DW, Swildens-van Woudenberg IA, et al. (1999) Holmium-166 poly lactic acid microspheres applicable for intra-arterial radionuclide therapy of hepatic malignancies: effects of preparation and neutron activation techniques. Eur J Nucl Med 26: 699-704.
18. Seevinck PR, Seppenwoolde JH, de Wit TC, Nijsen JF, Beekman FJ, et al. (2007) Factors affecting the sensitivity and detection limits of MRI, CT, and SPECT for multimodal diagnostic and therapeutic agents. Anticancer Agents Med Chem 7: 317-334.
19. Seevinck PR, van de Maat GH, de Wit TC, Vente MA, Nijsen JF, et al. (2012) Magnetic resonance imaging-based radiation-absorbed dose estimation of 166Ho microspheres in liver radioembolization. Int J Radiat Oncol Biol Phys 83: 437-444.
20. Zielhuis SW, Nijsen JF, Figueiredo R, Feddes B, Vredenberg AM, et al. (2005) Surface characteristics of holmium-loaded poly(L-lactic acid) microspheres. Biomaterials 26: 925-932.
21. Bult W, de Leeuw H, Steinebach OM, van der Bom MJ, Wolterbeek HT, et al. (2012) Radioactive Holmium Acetylacetonate Microspheres for Interstitial Microbrachytherapy: An In Vitro and In Vivo Stability Study. Pharm Res 29: 827-36.
22. van der Have F, Vastenhouw B, Ramakers RM, Branderhorst W, Krah JO, et al. (2009) U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging. J Nucl Med 50: 599-605.
23. Branderhorst W, Vastenhouw B, Beekman FJ, (2010) Pixel-based subsets for rapid multi-pinhole SPECT reconstruction. Phys Med Biol 55: 2023-2034.
24. van der Have F, Vastenhouw B, Rentmeester M, Beekman FJ, (2008) System calibration and statistical image reconstruction for ultra-high resolution stationary pinhole SPECT. IEEE Trans Med Imaging 27: 960-971.
25. Bolch WE, Bouchet LG, Robertson JS, Wessels BW, Siegel JA, et al. (1999) MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee. J Nucl Med 40: 11S-36S.
26. Hendricks JSM, McKinney GW, Waters LS, Roberts TL, Egdorf HW, et al. (2005) MCNP Extention, Version 2.5.0. Los Alamos: Los Alamos National Laboratory Report. LA-UR-05-2675: 1-70 p.
27. Forrer F, Rolleman E, Bijster M, Melis M, Bernard B, et al. (2007) From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99 m)Tc-DMSA-SPECT and molecular imaging. Cancer Biother Radiopharm 22: 40-49.
28. Madrazo A, Suzuki Y, Churg J, (1969) Radiation nephritis: acute changes following high dose of radiation. Am J Pathol 54: 507-527.
29. Vente MA, Nijsen JF, de Wit TC, Seppenwoolde JH, Krijger GC, et al. (2008) Clinical effects of transcatheter hepatic arterial embolization with holmium-166 poly(L-lactic acid) microspheres in healthy pigs. Eur J Nucl Med Mol Imaging 35: 1259-1271.
30. D'Asseler Y, (2009) Advances in SPECT imaging with respect to radionuclide therapy. Q J Nucl Med Mol Imaging 53: 343-347.
31. de Wit TC, Xiao J, Nijsen JF, van het Schip FD, Staelens SG, et al. (2006) Hybrid scatter correction applied to quantitative holmium-166 SPECT. Phys Med Biol 51: 4773-4787.
32. Vanhove C, Defrise M, Bossuyt A, Lahoutte T, (2009) Improved quantification in single-pinhole and multiple-pinhole SPECT using micro-CT information. Eur J Nucl Med Mol Imaging 36: 1049-1063.
33. O'Donoghue J, (2004) Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm 19: 378-387.
34. Zielhuis SW, Nijsen JF, Seppenwoolde JH, Bakker CJ, Krijger GC, et al. (2007) Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats. Biomaterials 28: 4591-4599.
35. Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, et al. (2010) Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res 29: 70.
36. Smits MLJ, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, et al. (2012) Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol 13: 1025-34.
37. Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR, (2005) Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 185: 64-71.
38. Luboldt W, Pinkert J, Matzky C, Wunderlich G, Kotzerke J, (2009) Radiopharmaceutical tracking of particles injected into tumors: a model to study clearance kinetics. Curr Drug Deliv 6: 255-260.
39. Hung AJ, Ma Y, Zehnder P, Nakamoto M, Gill IS, et al. (2012) Percutaneous radiofrequency ablation of virtual tumours in canine kidney using Global Positioning System-like technology. BJU Int 109: 1398-403.